Preclinical R&D Services for Cholecystitis

With extensive expertise in hepatobiliary research, Ace Therapeutics provides professional preclinical research services to advance both fundamental understanding and therapeutic development for cholecystitis, supporting meaningful breakthroughs in the field.

Overview of Cholecystitis

Cholecystitis, an inflammatory condition of the gallbladder, typically results from bacterial infection or chemical irritation and presents as either acute or chronic forms. Primary etiological factors include gallstones (cholelithiasis), gallbladder neoplasms, biliary obstruction disorders, and bacterial infections caused by Escherichia coli or Enterococcus species.

Fig. 1 2020 WSES Flowchart for the management of patients with acute calcolus cholecystitis. (Pisano M, et al., 2020)

Custom Cholecystitis Animal Models

Leveraging our extensive experience in hepatobiliary disease modeling, we design and optimize physiologically relevant cholecystitis animal models tailored to specific research objectives.

Drug Development Services for Cholecystitis

Drug Target Identification and Validation Services

• Transcriptome and Proteomics Analysis
  Based on our integrated transcriptomic and proteomic analysis platform, we systematically characterize dysregulated inflammatory pathways in cholecystitis pathogenesis, including TLR4/NF-κB signal transduction, NLRP3 inflammasome activation dynamics, and bile acid receptor (FXR/TGR5) signaling network perturbations, providing mechanistic insights that enable identification of novel therapeutic targets.
• Microbiome Analysis
  Utilizing high-throughput 16S rRNA and metagenomic sequencing of cholecystitis-associated microbiota (with particular focus on E. coli and Klebsiella spp. dynamics), we facilitate discovery of novel antimicrobial agents and microbiome-modulating interventions with enhanced gallbladder tissue specificity.

Drug Screening and Discovery Services

• Cell-based Drug Screening
  Our standardized screening system employs immortalized gallbladder epithelial cells (GBEC) to establish inflammation models induced by LPS or bile acid, enabling quantitative evaluation of therapeutic candidates through sensitive ELISA-based measurement of IL-6 and IL-8 secretion profiles.
• Anti-Microbial Efficacy Screening
  We assess the therapeutic potential of drug candidates against prevalent cholecystitis pathogens (e.g., E. coli, enterococci) using minimum inhibitory concentration (MIC) assays, providing critical data on antimicrobial activity spectrum and potency to guide development of targeted biliary infection therapies.

Preclinical Drug Development Services

• In Vitro Drug Efficacy Analysis
  We developed a human gallbladder epithelial cell (HGBEC) model that recapitulates key pathological features of cholecystitis through physiologically relevant stimulation with LPS and bile salts. This advanced model enables comprehensive mechanistic evaluation of drug candidates through quantitative analysis of tight junction integrity, inflammatory mediator production, and programmed cell death pathways, providing robust preclinical data for cholecystitis therapeutic development.
• Antimicrobial Activity Testing
  Our innovative screening platform enables rapid identification of promising antimicrobial candidates for cholecystitis treatment through simultaneous assessment of bactericidal activity (quantitative MIC/MBC determination) and biofilm eradication capacity (high-throughput quantification against clinically relevant E. coli and Klebsiella spp. biofilms).
• Bile Metabolism Analysis
  Our integrated bile analysis platform enables systematic characterization of drug candidates' effects on critical biliary components, including cholesterol solubility enhancement, bilirubin precipitation inhibition, and bile acid profile modulation, facilitating the development of novel bile-modifying therapeutics for cholecystitis management.
• Hepatobiliary Functional Analysis
  Through advanced co-culture systems incorporating hepatocytes (HepG2) and cholangiocytes (H69), we perform comprehensive assessment of drug effects on bile acid metabolism, including synthesis pathway modulation and transporter function regulation, offering mechanistic insights for developing cholecystitis therapeutics that restore biliary homeostasis.

Ace Therapeutics has a team of professionals in the field of hepatobiliary disease research. We will provide the custom service program for cholecystitis drug development according to clients' experimental needs. If you would like to learn more about our services, please do not hesitate to contact us.

Reference

1. Pisano, M.; et al. 2020 World Society of Emergency Surgery updated guidelines for the diagnosis and treatment of acute calculus cholecystitis. World J Emerg Surg. 2020, 15(1):61.

Our products and services are for research use only and can not be used for diagnostic or other purposes.